Canasa

— THERAPEUTIC CATEGORIES —
  • Colorectal disorders
PAGE CONTENTS
  • Jump to Section
  • Generic Name & Formulations
  • Indications
  • Dosage and Administration
  • Contraindications
  • Boxed Warnings
  • Warnings/Precautions
  • Pharmacokinetics
  • Interactions
  • Adverse Reactions
  • Clinical Trials
  • Note
  • Patient Counseling

    • Canasa Generic Name & Formulations

    Legal Class

    Rx

    General Description

    Mesalamine 1g; supps.

    Pharmacological Class

    Aminosalicylate.

    How Supplied

    Supps—30, 42

    Manufacturer

    AbbVie

    Generic Availability

    YES

    Mechanism of Action

    The mechanism of action of mesalamine is not fully understood, but appears to be a topical anti-inflammatory effect on colonic epithelial cells. Mucosal production of arachidonic acid metabolites, both through the cyclooxygenase pathways (eg, prostanoids), and through the lipoxygenase pathways (eg, leukotrienes and hydroxyeicosatetraenoic acids), is increased in patients with ulcerative colitis, and it is possible that mesalamine diminishes inflammation by blocking cyclooxygenase and inhibiting prostaglandin production in the colon.

    Canasa Indications

    Indications

    Mild to moderately active ulcerative proctitis.

    Canasa Dosage and Administration

    Adult

    Retain supp in rectum for at least 1–3hrs. 1g once daily at bedtime. Treat for 3–6 weeks.

    Children

    Not established.

    Canasa Contraindications

    Not Applicable

    Canasa Boxed Warnings

    Not Applicable

    Canasa Warnings/Precautions

    Warnings/Precautions

    Sulfasalazine allergy. Discontinue if acute intolerance syndrome is suspected. Discontinue at the 1st signs/symptoms of severe cutaneous adverse reactions. Conditions predisposing to myocarditis or pericarditis. Atopic dermatitis or eczema: may have more severe photosensitivity reactions. Nephrolithiasis. Ensure adequate hydration. Renal or hepatic impairment. History of renal disease. Assess renal function prior to and periodically during therapy. Discontinue if renal function deteriorates while on therapy. May stain clothes. Elderly (monitor CBCs, platelets). Pregnancy. Nursing mothers: monitor infants.

    Canasa Pharmacokinetics

    Absorption

    Mean peak plasma concentration (Cmax): 353 ng/mL (after the initial dose); 361 ng/mL (at steady state). Mean minimum steady state plasma concentration (Cmin): 89 ng/mL.

    Distribution

    Distributes in rectal tissue to some extent.

    Metabolism

    Hepatic.

    Elimination

    Renal. Half-life: 5 hours (after the initial dose); 7 hours (at steady state).

    Canasa Interactions

    Interactions

    Increased toxicity with nephrotoxic drugs (eg, NSAIDs). Increased risk for blood disorders, bone marrow failure, and associated complications with azathioprine or 6-mercaptopurine and/or other drugs known to cause myelotoxicity. May cause elevated test results when measuring urinary normetanephrine; consider other alternative assay.

    Canasa Adverse Reactions

    Adverse Reactions

    Dizziness, rectal pain, fever, rash, acne, colitis, headache, flatulence, abdominal pain, diarrhea, nausea; renal impairment, mesalamine-induced acute intolerance syndrome, hypersensitivity reactions, severe cutaneous adverse reactions (eg, SJS, TEN, DRESS, AGEP).

    Canasa Clinical Trials

    See Literature

    Canasa Note

    Not Applicable

    Canasa Patient Counseling

    See Literature

    • Latest News Your top articles for Wednesday

    • Haymarket Medical NetworkTop Picks

    • Loading...

      Continuing Medical Education (CME/CE) Courses

      Show More